Several studies have proposed a relationship between blood pressure and inflammation. Interleukin-6 (IL-6) is a multifunctional cytokine involved in inflammation and tissue injury and potentially influencing blood pressure. Recently, a common polymorphism of the IL-6 gene, associated with differences in the transcription rate of the protein, has been described. The aim of this study was to investigate a possible association between genetic variations of the −174GC polymorphism of the IL-6 gene promoter and hypertension in humans. IL-6 gene promoter polymorphism was evaluated by polymerase chain reaction followed by restriction enzyme analysis in 210 elderly Italian patients affected by essential
Introduction
There is an accumulating body of evidence indicating that alterations of the immune system are involved in the cascade of events leading to essential hypertension (EH). 1, 2 Various types of auto-antibodies, altered number and function of T-lymphocytes, and the relationship with certain HLAgenotypes have been reported in patients with EH. 3, 4 Hypertensive patients have an increased inflammatory cytokine production capacity when whole blood is stimulated ex vivo with lipopolysaccharide. 5 Similarly, in spontaneously hypertensive rats, a series of disturbances of the humoral and cellular immune response are present. 6 Interleukin-6 (IL-6) is an important component of the pro-inflammatory response and may be secreted by several tissues and cell types, including monocytes and macrophages, T and B-cells, fibroblasts, bone marrow stromal cells, endothelial cells, hepatocytes, smooth muscle cells, and adipose tissue. 7 IL-6 plays a key role in driving the acute inflammatory response and orchestrates the production of acute phase proteins. 8 Elevated levels of IL-6 are found in patients with coronary syndromes 9 and have been associated with increased risk of future myocardial infarction in an apparently healthy population. 10 A relationship between IL-6 and EH may be hypothesised for a number of reasons. First, IL-6 stimulates fibrinogen synthesis, 11 which is a main determinant of blood viscosity 12 and may be directly pathogenic to the endothelium. In addition, both blood viscosity and fibrinogen are positively correlated with blood pressure. 13 Second, IL-6 influences the expression of angiotensinogen, 14, 15 thus leading to higher concentration of the potent vasocostrictor angiotensin II. Interestingly, stimulation of human vascular smooth muscle cells by angiotensin II results in inflammatory activation
Journal of Human Hypertension with dose-dependent increase in expression and release of IL-6. 16 Third, up to 30% of circulating IL-6 is produced by the adipose tissue 17, 18 and the relationship between obesity and hypertension is well known. Finally, IL-6 increases collagen synthesis in the vessel wall 19 and reduces its degradation. 20 Therefore, it is possible that high levels of IL-6 might affect vascular compliance and blood pressure over time.
Recently, a common genetic polymorphism has been reported in the −174 promoter region of the IL-6 gene. 21 Two different alleles can be identified (G and C allele), resulting in three possible genotypes, GG, GC, and CC. This polymorphism is functionally important, since it influences the transcription rate of the gene and the plasma concentration of the IL-6 protein. 21, 22 The aim of this study was to evaluate the hypothesis that the IL-6 gene polymorphism is associated with EH. We analysed the distribution of IL-6 genotypes and alleles in a case-control study including 210 EH patients and 177 control subjects.
Methods

Subjects
Patients and controls were recruited from among subjects older than 65 years consecutively admitted to the Department of Medicine of the A. Gemelli University Hospital of Rome, from December 2000 to November 2001. Exclusion criteria were secondary hypertension, tumours, chronic inflammatory diseases, and autoimmune diseases. Hypertension was defined as current treatment with an antihypertensive drug or a diastolic blood pressure with a minimum of 90 mm Hg and/or a systolic blood pressure with a minimum of 140 mm Hg, the average of the readings obtained on at least three different previous occasions. Blood pressure was determined using a mercury sphygmomanometer in a supine position, after a 10-min resting period, three readings per visit. A complete medical history was collected for all patients and included smoking habit, alcohol consumption, presence of diabetes, history of cardiovascular diseases, and drug treatment. Peripheral venous blood samples were taken for determination of lipid profile, as well as for IL-6 polymorphism analysis.
A total of 210 EH patients and 177 controls were enrolled. All subjects were Caucasians born and resident in Italy and belonged to independent pedigrees. Patients and controls were matched for age and sex: the mean age was 77.2 ± 6.4 years in the patient group and 77.2 ± 6.2 years in the control group (P = 0.971); the male/female ratio was 98/112 in the patient group and 77/100 in controls (P = 0.53). Informed consent was obtained from all patients. The study protocol was accepted by the Ethics Committee of our University Hospital.
Sample preparation and PCR detection of IL-6 DNA polymorphism
DNA was extracted from peripheral blood and assayed by polymerase chain reaction (PCR) and restriction enzyme analysis for the detection of the IL-6 gene, as previously described. 23 After digestion with SfaNI restriction enzyme (New England BioLabs, Beverly, MA, USA) at 37°C overnight, products were electrophoresed in 2% agarose gel and visualised by ethidium bromide staining. The GG genotype corresponded to the contemporary presence of 140 and 58 bp fragments. The GC genotype corresponded to the contemporary presence of 198, 140, and 58 bp fragments. The CC genotype corresponded to a 198 bp fragment.
Statistical analysis
Demographic and clinical data between groups were compared by chi-square test and t-test. Genotype and allele frequencies were compared by chi-square test. All analyses were done by using Intercooled STATA 6.0 for Windows (Statistics/Data Analysis, Stata Corporation, College Station, TX, USA). Statistical significance was established at P Ͻ 0.05.
Results
The demographic and clinical data of EH and control subjects are shown in Table 1 . There were no significant differences between groups in terms of age, sex, smoking (current and former), hypercholesterolaemia, and diabetes (P = NS). As expected, history of cerebrovascular disorders (32.9% vs 13%, P Ͻ 0.0001), history of coronary artery disease (CAD) (34.3% vs 20.3%, P = 0.002), and peripheral artery occlusive disease (PAOD) (18.1% vs 6.2%, P Ͻ 0.0001) were more frequent in EH patients than controls.
The distribution of IL-6 genotypes and alleles in cases and controls is shown in Table 2 . Genotypes were in Hardy-Weinberg equilibrium. Their distribution was 85 GG, 88 GC, 37 CC in the 210 patients with EH and 65 GG, 73 GC, 39 CC in the 177 control subjects and was not statistically different between the two groups (P = 0.450, P = 0.895, P = 0.276, respectively). Likewise, allele distribution was not significantly different: the G allele frequency was 61.4% in patients and 57.3% in controls, while the C allele frequency was 38.6% in the patients with EH and 42.7% in controls. The ratio between G and C allele frequency was 1.89 in patients and 1.34 in controls (P = 0.31).
Discussion
The study presented here was based on the hypothesis that variation in the promoter region of the IL-6 gene might be associated with systemic hypertension. Interestingly, IL-6 activity and plasma levels have been associated with several hypertensioninduced disturbances, in particular atherosclerosis. 24 Immunohistochemical studies of the human arterial atherosclerotic wall have demonstrated that IL-6 is expressed in the cellular and extracellular deposits in the connective tissue matrix and that atherosclerotic plaques have high levels of IL-6. 25 Studies in ApoE-knockout mice, that spontaneously develop systemic atherosclerosis, also show elevated levels of IL-6 mRNA in the plaque area compared with normal mice. 26 On the other hand, several studies have investigated the possible clinical significance of IL-6 gene variants and analysed their association with atherosclerotic disorders, including carotid atherosclerosis, CAD, and abdominal aortic aneurysm. 25, 27, 28 Following these observations, our study was designed in order to analyse the association between a common polymorphism of the IL-6 gene promoter and EH. A recent study, performed in Japanese women, has found a weak association between some polymorphisms of the IL-6 gene promoter and hypertension. 29 This study analysed the C/G substitution at −634, the G/A substitution at 4391 in a 3Ј non-coding portion of exon 5, and the A/T variation in the −447 position. However, all these gene variants are different from that investigated in our study. In addition, the gene polymorphism analysed here is the only one for which an influence on IL-6 plasma levels has been demonstrated. 21 In our population, composed of elderly Italians, the frequency of the three IL-6 genotypes (GG, Journal of Human Hypertension GC, CC) was not statistically different between patients with EH and controls (P = 0.450, P = 0.895, P = 0.276 respectively). Likewise, the allele distribution was not different between groups (P = 0.31).
This study has some potential limitations. It is a case-control study and a possible survival bias cannot be excluded for the patients with EH. We did not analyse the plasma levels of IL-6. However, IL-6 protein levels are influenced by many pathologic and physiologic conditions, such as infections, autoimmune disorders, malignancies, trauma, ischaemia, and drug treatment. [30] [31] [32] Therefore, a single measurement might be not predictive of disease in a given individual. For this reason, our study was focused on the analysis of a polymorphism that genetically determines the plasmatic levels of IL-6. 21, 22 In addition, we cannot exclude a role played by a gene or by several genes in linkage disequilibrium with IL-6, nor that a variant of another gene, closely linked to the IL-6 gene, causes the observed association. The human IL-6 gene is located on chromosome 7p21. 33 There is strong linkage disequilibrium between the IL-6 gene promoter polymorphism and the variable number of tandem repeat polymorphism of the 3Ј flanking region of the IL-6 gene. 34 The IL-6 gene is also closely linked to the interferonbeta 2 (IFNB2) and hepatocyte stimulating factor (HSF) genes. 33 Finally, the human growth arrest-specific homeobox (Gax) gene, which is involved in the signalling pathway of Angiotensin II-induced vascular growth, is also located on chromosome 7p21. 35 In conclusion, our data indicate that, in an elderly Italian population, the −174 G/C polymorphism of the IL-6 gene promoter does not contribute to the genetic susceptibility of EH.
